Cat. No. 4132
Chemical Name: 2-[[2-Ethoxy-4-(4-hydroxy-1-piperid
Biological ActivityERK5 (BMK1) and BRD4 inhibitor (Kd values are 80 and 190 nM, respectively). Also inhibits DCAMKL2, PLK4 and TNK1 (Kd values are 190, 600 and 890 nM). Blocks growth factor-induced activation of cellular BMK1 and reduces BMK1 activity in in vitro kinase assays. Also reduces BMK1-dependent transactivating activity of MEF2C. Inhibits proliferation in a variety of cancer cell lines; blocks tumor cell proliferation and tumor-associated angiogenesis.
Licensing InformationSold under license from the Dana-Farber Cancer Institute.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of XMD 8-92 is reviewed on the chemical probes website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Lin et al (2016) ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc.Natl.Acad.Sci.U.S.A. 113 11865. PMID: 27679845.
Erazo et al (2013) Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol.Cell Biol. 33 1671. PMID: 23428871.
Deng et al (2011) Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med.Chem.Lett. 2 195. PMID: 21412406.
Yang and Lee (2011) Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin.Cancer Res. 17 3527. PMID: 21385929.
Yang et al (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18 258. PMID: 20832753.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for XMD 8-92 include:
Simões et al (2015) Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death Dis 6 e1718. PMID: 25855966.
Al-Ejeh et al (2014) Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Mediators Inflamm 5 3145. PMID: 24762669.
Do you know of a great paper that uses XMD 8-92 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: XMD 8-92, supplier, erk5, bmk1, big, MAP, kinase, 1, inhibitors, inhibits, antitumor, antiproliferative, antiproliferation, XMD8-92, bromodomains, BRD4, Tocris Bioscience, ERK Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective p38α/β inhibitor; orally bioavailableAX 15836
Potent and selective ERK5 inhibitor
Win a $1,000 travel grant
Bio-Techne is offering 10 travel grants of $1,000 for AACR 2017.